A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
CRA strengthens its Antitrust & Competition Economics Practice
“We are pleased to welcome Nate to CRA’s Antitrust & Competition Economics Practice,” said Paul Maleh, President and Chief Executive Officer of Charles River...